Going back to class I: MHC and immunotherapies for childhood cancer. Issue 4 (18th December 2014)

• Record Type: Journal Article
• Authors: Haworth, Kellie B.; Leddon, Jennifer L.; Chen, Chun‐Yu; Horwitz, Edwin M.; Mackall, Crystal L.; Cripe, Timothy P.
• Is Part Of: Pediatric blood & cancer. Volume 62:Issue 4(2015:Apr.)
• Page Start: 571
• Page End: 576
• Publication Date: 2014-12-18
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25359
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25359-sec-0001" sec-type="section"> <p>After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T‐cell versus NK‐mediated therapies, and strategies to reverse or circumvent MHC down‐regulation.Pediatr Blood Cancer 2015;62:571–576. © 2014 The Authors. <italic>Pediatric Blood &amp; Cancer</italic> published by Wiley Periodicals, Inc.</p> </sec> </abstract>